Use of totally implantable central venous access port via the basilic vein in patients with thoracic malignancies

• Published in: International journal of clinical oncology 2009-06, Vol.14 (3), p.208-212
• Main Authors: Sonobe, Makoto, Chen, Fengshi, Fujinaga, Takuji, Sato, Kiyoshi, Shoji, Tsuyoshi, Sakai, Hiroaki, Miyahara, Ryo, Bando, Toru, Okubo, Kenichi, Hirata, Toshiki, Date, Hiroshi
• Format: Article
• Language: English
• Subjects: Adult; Aged; Cancer Research; Catheterization, Central Venous - adverse effects; Catheters, Indwelling - adverse effects; Chemotherapy; Drug delivery systems; Female; Forearm - blood supply; Humans; Lung cancer; Lung Neoplasms - drug therapy; Male; Medicine; Medicine & Public Health; Middle Aged; Oncology; Original Article; Retrospective Studies; Surgical Oncology; Transplants & implants; Vena Cava, Superior
• ISSN: 1341-9625; 1437-7772
• DOI: 10.1007/s10147-008-0835-6

Background For patients with a thoracic malignancy whose peripheral veins are not suitable for blood access for chemotherapy, we evaluated a totally implantable central venous access port, in which the port is implanted in the ulnar side of the arm and the catheter is introduced via the basilic vein into the superior vena cava (TIAP-BV). Methods Twenty-five patients (21 with lung cancer, 2 with malignant pleural mesothelioma, and 2 with thymoma) receiving TIAP-BV were included. Indications, surgical complications, and long-term complications were analyzed. Results Indications for TIAP-BV were: chemotherapy (17 patients) and chemotherapy with parenteral nutrition (8 patients). The following surgical complications occurred: arrhythmia due to misplacement of the tip of catheter (1 patient); intraoperative conversion from the left to right arm (2 patients); and hematoma at the implantation site (1 patient). Short-term problems were: death 1 week after implantation without the use of TIAP-BV (2 patients). Long-term complications were: skin ulcer at the port site (1 patient); early removal of TIAP-BV because of port site infection (1 patient); catheter occlusion (1 patient); and venous thrombosis of basilic vein (2 patients). In the 22 patients who did not die early or have the device withdrawn early, the median duration of TIAP-BV use was 7 months (range, 1 to 20 months) without any break to the port system, leakage of drugs, or catheter-related infections. Conclusion TIAP-BV can be employed for long-term use for chemotherapy and parenteral nutrition. However, a patient’s expected prognosis and infectious disease status at the time of implantation surgery should be considered before the surgery proceeds.